SG/PUT/MODERNA/140/0.1/21.03.25 | Market Closed - Börse Stuttgart 01:20:12 04/07/2024 am IST | ||
| 3.27 EUR | +0.31% |
|
| Current month | +4.14% | ||
| 1 month | +63.50% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 04/24/04 | 3.27 | +0.31% |
| 02/24/02 | 3.26 | -0.91% |
| 01/24/01 | 3.29 | +4.78% |
| 28/24/28 | 3.14 | +4.67% |
| 27/24/27 | 3 | +1.01% |
Delayed Quote Börse Stuttgart
Last update July 04, 2024 at 01:20 am IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| WKN | SY0NV0 |
| ISIN | DE000SY0NV05 |
| Date issued | 21/05/2024 |
| Strike | 140 $ |
| Maturity | 21/03/2025 (261 Days) |
| Parity | 10 : 1 |
| Emission price | 2.52 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.41 € |
|---|---|
| Lowest since issue | 1.55 € |
| Spread | 0.04 € |
| Spread % | 1.21% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
116
USD
Average target price
145.9
USD
Spread / Average Target
+25.79%
- Stock Market
- Warrants
- Warrant
